Inclusion Criteria:

          -  Cohort A: Received a minimum of 1 to a maximum of 3 prior lines of therapy including a
             proteasome inhibitor (PI) and immunomodulatory therapy (IMiD), and lenalidomide
             refractory per International Myeloma Working Group (IMWG) guidelines

          -  Cohort B: Received one line of prior therapy including a PI and an IMiD, and disease
             progression per IMWG criteria less than or equal to (<=) 12 months after treatment
             with autologous stem cell transplantation (ASCT) or <=12 months from the start of
             anti-myeloma therapy for participants who have not had an ASCT

          -  Cohort C: Previously treated with a PI, an IMiD, an anti-CD38 monoclonal antibody and
             B-cell maturation antigen (BCMA)-directed therapy

          -  Cohort D: Newly diagnosed multiple myeloma per IMWG with a history of 4 to 8 total
             cycles of initial therapy, including induction, high-dose therapy, and ASCT with or
             without consolidation

          -  Cohort E: Have newly diagnosed multiple myeloma without prior therapy (one cycle of
             prior therapy before enrollment is acceptable) and classified as high risk defined as
             either: 1) International Staging System (ISS) stage III criteria, Beta 2 microglobulin
             greater than or equal to (>=) 5.5 milligram per liter (mg/L) (via local or central
             laboratory assessment) or 2) high risk cytogenetic features del(17/17p), t (14;16),
             t(14;20), 1q amplification (at least 4 copies)

        Cohorts A, B, C, E:

          -  Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram
             per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours

          -  Light chain multiple myeloma in whom only measurable disease is by serum free light
             chain (FLC) levels in the serum: Serum immunoglobulin FLC >=10 mg/dL and abnormal
             serum immunoglobulin kappa lambda FLC ratio

          -  Cohort A: For participants with neither serum nor urine measurable disease, baseline
             positron emission tomography/ computed tomography (PET/CT) or whole -body magnetic
             resonance imaging (MRI) may be used to satisfy the measurable disease criteria. A
             minimum of one lesion with a bi-dimensional measurement of at least 1 centimeter
             (cm)*1 cm is required

          -  Cohorts B, C: For participants with neither serum nor urine measurable disease,
             baseline positron emission tomography/ computed tomography (PET/CT) or whole body
             magnetic resonance imaging (MRI) may be used to satisfy the measurable disease
             criteria

          -  Cohorts A, B, C, D, E, F: Eastern Cooperative Oncology Group (ECOG) performance status
             grade of 0 or 1

          -  Cohort F: Participant must have a documented efficacy response of very good partial
             response (VGPR) or better, without progressive disease prior to enrollment, as
             assessed per IMWG 2016 criteria

        Exclusion Criteria:

          -  Cohorts A, B, D, F: Any therapy that is targeted to BCMA

          -  Cohorts A, B, C, D, F: Prior treatment with chimeric antigen receptor T (CAR-T)
             therapy directed at any target

        Cohorts A, B, C, D, F:

          -  Ongoing toxicity from previous anticancer therapy must resolve to baseline levels or
             to Grade 1 or less except for alopecia or peripheral neuropathy

          -  Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone
             within the 7 days (Cohort A, B, C, F) or 14 days (Cohort D) prior to apheresis

          -  Serious underlying medical condition, such as (a) evidence of active viral or
             bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic
             fungal infection; (b) active autoimmune disease or a history of autoimmune disease
             within 3 years; (c) overt clinical evidence of dementia or altered mental status; (d)
             any history of Parkinson's disease or other neurodegenerative disorder

          -  Cohorts A, B, C, D, E, F: Known active, or prior history of central nervous system
             (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple
             myeloma